Compare BioNTech SE - ADR (BNTX) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Peloton Interactive Inc — how do they compare? BioNTech SE - ADR trades at $92 (market cap $23.31B), while Peloton Interactive Inc trades at $5.57 (market cap $2.46B). The key difference: BioNTech SE - ADR is far larger — about 9.5× Peloton Interactive Inc's market cap, and Peloton Interactive Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | PTON | |
|---|---|---|
Market Cap | $23.31B | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $9.00 |
52-Week Low | $83.89 | $3.71 |
Enterprise Value | $6.60B | $2.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Peloton Interactive (PTON) trades at $5.51, down 2.99% on the day, reflecting ongoing investor caution despite achieving its first annual net profit in fiscal 2026. The stock shows a bearish technical trend with key support at $5, while fundamentals reveal a mixed picture: revenue declined to $2.49B in 2025 but net losses narrowed significantly, with a positive net income margin of 2.58% projected for 2026. Recent news highlights profitability milestones but also subscriber declines and a conservative 2027 outlook.
The outlook remains cautious; profitability improvements and cost control are positive, but persistent revenue erosion and high debt levels pose risks. Analyst sentiment is divided with a 50% buy rating, yet the stock's proximity to support levels suggests potential for stability if execution continues. Key risks include subscriber retention and competitive pressures in the fitness market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
